
Please try another search
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is focused on drug development for infectious diseases and biodefense. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a biological weapon threat, a topical antiparasitic product for the treatment of a disfiguring disease, an antifungal and two antibiotic programs. Its anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503 and ATI-1501. The ATI-2307 is used for the treatment of invasive fungal infections with a near-term focus on those caused by Cryptococcus and Candida. The ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The ATI-1503 is a drug discovery program builds off the molecular structure of negamycin, a naturally occurring compound that can kill Gram-negative bacteria. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole. Its anti-infective portfolio includes ATI-1801.
Name | Age | Since | Title |
---|---|---|---|
Lidija Marusic | - | 2019 | Board Observer |
Dean L. Shinabarger | - | - | Member of Advisory Board |
Sridhar Narayan | - | - | Member of Scientific Advisory Board |
Josef Vejvoda | 56 | 2021 | Director |
Juergen Froehlich | 64 | 2020 | Independent Director |
Lynn L. Silver | - | - | Member of Advisory Board |
Brian Matthew Bloom | 44 | 2015 | Director |
Rochelle E. Stenzler | 67 | 2021 | Independent Director |
Theresa Matkovits | 55 | 2018 | Lead Independent Director |
Armand Balboni | 56 | 2019 | Chairman of the Board |
Donald D. Cilla | - | 2020 | CEO, President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review